Actuate Therapeutics, Inc. ACTU 深 沪
等待开盘 05-21 09:30:00 美东时间
2.51
+0.110
+4.58%
华盛通- 最 高2.62
- 今 开2.39
- 成交量 5.63万股
- 最 低 2.39
- 昨 收 2.40
- 总市值 6005.39万
- 52周最高 11.70
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 1.58
- 委 比 -1.99%
- 总股本 2392.59万
- 历史最高 11.99
- 量 比 0.72
- 振 幅 9.58%
- 历史最低 1.58
- 每 手 1
- 风险率 2.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Actuate Therapeutics Announces FDA Clearance Of IND For Phase 1/2 Study Of Oral Elraglusib In Advanced Cancer Patients, With Focus On Metastatic Melanoma, NSCLC, Colorectal, And Pancreatic Cancers With Initiation Planned For 2H 2026
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma,
05-11 19:08
美股大行评级 | 巴克莱大幅上调希捷科技、西部数据目标价！联合健康、霍顿房屋、盈透证券、奎斯特诊疗等获多家机构上调目标价
今日重点评级关注：Piper Sandler：维持MeiraGTx Holdings"超配"评级，目标价从26美元升至30美元；康托·菲茨杰拉德：维持MKS Inc."超配"评级，目标价从300美元升至400美元
04-23 12:35
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
04-22 19:59
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?
Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.
04-16 15:34
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BNB Plus (NASDAQ:BNBX) stock moved upwards by 12.7% to $0.65 during Tu...
04-15 05:05
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
04-13 20:45
HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $15
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $20 to $15.
04-13 18:57
Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitors
The combination strategy is designed to simultaneously block proliferative signaling through RAS inhibition and disrupt tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic
03-09 20:48
Actuate Therapeutics Intends To Initiate Phase 1/2 Clinical Program To Evaluate Oral Tablet Dosage Form Of Elraglusib In Patients With Advanced Cancer
Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the
01-21 21:51
